美諾華(603538.SH):子公司原料藥硫酸氫氯吡格雷(工藝B)獲得歐洲CEP證書
格隆匯9月13日丨美諾華(603538.SH)公佈,近日,公司控股子公司浙江燎原藥業股份有限公司(“燎原藥業”)收到歐洲藥品質量管理局簽發的硫酸氫氯吡格雷(工藝B)歐盟CEP證書(歐洲藥典適用性證書)。
藥品適應症:適用於預防動脈粥樣硬化血栓形成事件,如近期缺血性卒中、近期心肌梗死、急性冠脈綜合徵等。
藥理作用:為血小板聚集抑制劑,能選擇性地抑制ADP與血小板受體的結合,隨後抑制激活ADP與糖蛋白GPⅡb/Ⅲa複合物,從而抑制血小板的聚集,也可抑制非ADP引起的血小板聚集,不影響磷酸二酯酶的活性。通過不可逆地改變血小板ADP受體,使血小板的壽命受到影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.